by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Group results revealed rapid and enduring improvements in depressive symptoms post psilocybin. Increased responses to fearful and happy faces were observed in the right amygdala post-treatment, and right amygdala increases to fearful versus neutral faces were...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen’s d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Two main change processes were identified in relation to the treatment. The first concerned change from disconnection (from self, others, and world) to connection, and the second concerned change from avoidance (of emotion) to acceptance. A third theme concerned...
by EmpathiCSubstanceS | Aug 11, 2022 | Psychedelic Research
Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks. Whole-brain analyses revealed post-treatment decreases in CBF in the temporal cortex, including the amygdala. Decreased amygdala CBF...
by EmpathiCSubstanceS | Aug 4, 2022 | Addiction, Anxiety, Ayahuasca, Bipolar Disorder, Chronic Pain, MDMA Sassafras Molly, Psychedelic Medicine, Psychotropics
Serotonin is one of the chemical messengers (neurotransmitters) that carry signals between brain nerve cells (neurons). SSRIs block the reabsorption (reuptake) of serotonin into neurons. This makes more serotonin available to improve transmission of messages between...
